Mice previously treated with the combination of VIP-R antagonist and anti-PD1 had 100% survival after tumor rechallenge versus 0% long-term survival among mice that were initially treated with single agent anti-PD1 antibody (Fig. 5g). Here, VIPR1 is linked to neoplasm.